Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Summit sells failed antibiotic to OpenAI-backed startup in $105M deal

Summit sells failed antibiotic to OpenAI-backed startup in $105M deal

  • July 14, 2026

Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic drug candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront.

Leave A Comment

Fields (*) Mark are Required